The Hotel Council of San Francisco, in conjunction with the Leukemia & Lymphoma Society (LLS), will officially launch its "Million Dollar Mission" fundraising initiative on July 1 but early reports state that the mission has already gotten off to an impressive start.
Early donation commitments are already totaling in the thousands of dollars. Contributions are currently being accepted at www.donateSFMission.org.
Hotels and hospitality account for the second most employees in the city and are using their muscle to support the cause in various ways, including:
Furthermore, 'San Francisco is on sale' at BiddingForGood.com, where hotels in the Bay Area have created dozens of one-of-a-kind experiential packages that showcase the best of the San Francisco area. Auctions begin in July.
Expedia, Inc. is also helping out by supporting the mission through promoting it when visitors to their site search for San Francisco hotels.
Source: MarketWatch
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...